Pegylated IFNs for chronic hepatitis C: an update

Authors: Grace, Michael J; Cutler, David L; Bordens, Ronald W

Source: Expert Opinion on Drug Delivery, Volume 2, Number 2, 1 March 2005 , pp. 219-226(8)

Publisher: Informa Healthcare

Buy & download fulltext article:


Price: $99.00 plus tax (Refund Policy)


For over a decade, IFN-α2 has been the standard treatment for chronic hepatitis C. However, the drug’s rapid clearance and short half-life have led to low rates of sustained virological response. Pegylation is a well-established method of modifying the pharmacological properties of IFNs, causing significant improvements in pharmacokinetics, which in turn lead to improved efficacy. Two pegylated forms of IFN-α2 have been developed: PEG-IFN-α2b and PEG-IFN-α2a, and their efficacy has been established in randomised, -controlled trials. However, the two differ significantly in structure, invitro activity and pharmacological properties, and this may translate into -differences in clinical efficacy. Comparative trials have been initiated that will provide insight into relative importance of pharmacokinetics, bioactivity and dosing regimen.

Keywords: IFN-α2; chronic hepatitis C infection; pegylated IFN-α2a; pegylated IFN-α2b; ribavirin

Document Type: Review Article


Publication date: March 1, 2005

More about this publication?
Related content


Free Content
Free content
New Content
New content
Open Access Content
Open access content
Subscribed Content
Subscribed content
Free Trial Content
Free trial content

Text size:

A | A | A | A
Share this item with others: These icons link to social bookmarking sites where readers can share and discover new web pages. print icon Print this page